Amivantamab
Multispecific antibody
Evidence outlook
Approved: Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Colorectal Cancer · Phase 3 · investigational in the USHead and Neck Squamous Cell Carcinoma · Phase 3 · investigational in the US
Also approved (2)
- Treatment of unresectable advanced or recurrent epidermal growth factor receptor (EGFR) gene exon 20 insertion mutation-positive non-small cell lung cancer
- Conditional MA: EGFR exon 20 insertion NSCLC after platinum-based therapy (EPAR now lists four NSCLC indications)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
MARIPOSA NCT04487080 · Carcinoma, Non-Small-Cell Lung This was a randomized phase 3 trial of 1,074 people with an active comparator (osimertinib) and a hard progression-free survival endpoint that was clearly met. The amivantamab plus lazertinib arm was open-label; only the osimertinib and lazertinib-alone arms were blinded, so the main comparison was not blinded. Registry: NCT04487080 | 3 | Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)) 2023-08-11 | Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results. | Partial signal | link ↗ |
View 4 more trials
PAPILLON NCT04538664 · Carcinoma, Non-Small-Cell Lung This was a randomized phase 3 trial of 308 people with a chemotherapy control arm and a hard progression-free survival endpoint, reviewed by a blinded independent committee, that was clearly met. Treatment was open-label, so it is graded below the highest tier. Registry: NCT04538664 | 3 | Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 29 months)) 2023-05-03 | Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 29 months)): Arm A: Amivantamab + Chemotherapy 11.37 Months (95% CI 9.79 to 13.7) vs Arm B: Chemotherapy Alone 6.7 Months (95% CI 5.59 to 7.33) | Partial signal | link ↗ |
MARIPOSA-2 NCT04988295 · Carcinoma, Non-Small-Cell Lung This was a randomized phase 3 trial against a chemotherapy control with a hard progression-free survival endpoint that was clearly met in the main study. Treatment was open-label, so it is graded below the highest tier. Registry: NCT04988295 | 3 | Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)); Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) (up to 4 years 10 months); Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (Up to 4 years 10 months) 2023-07-10 | Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44) | Partial signal | link ↗ |
NCT04965090 NCT04965090 · Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer This was a 43-person, single-arm, open-label study without randomization, blinding, or a comparator group. Its primary endpoints were CNS overall response rates measured by RECIST/RANO criteria, but results are not posted, so the primary endpoint outcome is unavailable. Registry: NCT04965090 | 2 | CNS overall response rate (ORR) (Cohort 1) (2 years); measure CNS overall response rate (ORR) (Cohort 2) (2 years) 2025-12-15 | Results not posted; external-source review pending | Weak signal | link ↗ |
CHRYSALIS NCT02609776 · Non-Small Cell Lung Cancer Registry: NCT02609776 | 1 | Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Up to Day 28); Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs (Screening up to follow-up (30 [+7] days after the last dose)); Part 2: Overall Response Rate (ORR) (Up to End of Treatment Follow (EOT) Up Period (30 [+7] days after the last dose)); Part 2: Duration of Response (DOR) (Up to EOT Follow Up Period (30 [+7] days after the last dose)); Part 2: Percentage of Participants With Clinical Benefit (Up to EOT Follow Up Period (30 [+7] days after the last dose)); Trough Serum Concentration (Ctrough) of Amivantamab (Up to EOT (30 days after last dose)); Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab (Up to EOT (30 days after last dose)) 2026-12-31 | In progress: results expected 31 Dec 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2/3 (1)
What this study did
Competitive landscape
Other EGFR x c-MET drugs
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ALK202, Bafisontamab, Pamvatamig, SKB571 and 3 more. Compare all 9 EGFR x c-MET drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Amivantamab: this drug | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Encorafenib | Approved | Small molecule | BRAF V600E | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Approved | Small molecule | VEGFR1/2/3 | Reliable signal | NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis) | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016) | |
| Sotorasib | Approved | Small molecule | KRAS G12C | not yet graded | No reviewed efficacy summary in this indication | |
| Tucatinib | Approved | Small molecule | HER2 | Partial signal | NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| Becotatug | Phase 3 | Monoclonal antibody | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| Botensilimab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| HLX04 (Hanbeitai) | Phase 3 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| IBI363 | Phase 3 | Multispecific antibody | PD-1 x IL-2Rα (IL2RA) | not yet graded | No reviewed efficacy summary in this indication | |
| INCA33890 | Phase 3 | Multispecific antibody | TGF-βR2 and PD-1 (conditional bispecific) | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| S-1 | Phase 3 | Small molecule | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil) | not yet graded | No reviewed efficacy summary in this indication | |
| Telisotuzumab Adizutecan | Phase 3 | Antibody–drug conjugate | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| N-Dihydrogalactochitosan | Phase 2/3 | Polysaccharide | STING and inflammasome pathways | not yet graded | No reviewed efficacy summary in this indication | |
| DSP107 | Phase 2 | Protein / enzyme therapeutic | SIRP-alpha/4-1BBL fusion protein | not yet graded | No reviewed efficacy summary in this indication | |
| IBI305 | Phase 2 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Sirexatamab | Phase 2 | Monoclonal antibody | DKK1 (Dickkopf-1) | not yet graded | No reviewed efficacy summary in this indication | |
| A2B530 | Phase 1/2 | Cell therapy | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker) | not yet graded | No reviewed efficacy summary in this indication | |
| NC410 | Phase 1/2(overall) | Protein / enzyme therapeutic | Collagen (LAIR-1 ligands) | not yet graded | No reviewed efficacy summary in this indication | |
| BBO-10203 | Phase 1 | Small molecule | RAS:PI3Kα protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| KRAS-Specific Autologous TCR-T Cell | Phase 1(overall) | Cell therapy | KRAS G12V presented on HLA-A*11:01 | not yet graded | No reviewed efficacy summary in this indication | |
| LY01008 | Phase 1 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Palupiprant | Phase 1 | Small molecule | EP4 | Weak signal | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Tusamitamab Sonditecan | Phase 1 | Antibody–drug conjugate | CEACAM5 | not yet graded | No reviewed efficacy summary in this indication | |
| PI3Kalpha Precision Therapy | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(34 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Amivantamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (16)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
April 2027 (2)
May 2027 (4)
What to watch
What to watch
What to watch
What to watch
July 2027 (2)
What to watch
What to watch
August 2027 (1)
What to watch
October 2027 (2)
November 2027 (1)
What to watch
2028 (7)
March 2028 (1)
What to watch
May 2028 (2)
June 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (5)
February 2029 (2)
What to watch
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
2032 (1)
December 2032 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent